MX354481B - Anticuerpos dkk1 y métodos de uso. - Google Patents
Anticuerpos dkk1 y métodos de uso.Info
- Publication number
- MX354481B MX354481B MX2013004726A MX2013004726A MX354481B MX 354481 B MX354481 B MX 354481B MX 2013004726 A MX2013004726 A MX 2013004726A MX 2013004726 A MX2013004726 A MX 2013004726A MX 354481 B MX354481 B MX 354481B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- fragments
- methods
- dkk1 antibodies
- dkk1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos inmunológicamente funcionales de los mismos que enlazan específicamente polipéptidos DKK1. También se proporcionan métodos para preparar tales anticuerpos o fragmentos de los mismos así como composiciones fisiológicamente aceptables que contienen los anticuerpos o fragmentos de los mismos. También se describen el uso de los anticuerpos y fragmentos para tratar varias enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40712810P | 2010-10-27 | 2010-10-27 | |
PCT/US2011/058025 WO2012058393A2 (en) | 2010-10-27 | 2011-10-27 | Dkk1 antibodies and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013004726A MX2013004726A (es) | 2013-08-29 |
MX354481B true MX354481B (es) | 2018-03-07 |
Family
ID=44910313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013004726A MX354481B (es) | 2010-10-27 | 2011-10-27 | Anticuerpos dkk1 y métodos de uso. |
MX2021001494A MX2021001494A (es) | 2010-10-27 | 2013-04-26 | Anticuerpos dkk1 y metodos de uso. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001494A MX2021001494A (es) | 2010-10-27 | 2013-04-26 | Anticuerpos dkk1 y metodos de uso. |
Country Status (10)
Country | Link |
---|---|
US (3) | US9879072B2 (es) |
EP (3) | EP3838922A1 (es) |
JP (2) | JP6066912B2 (es) |
AR (2) | AR083740A1 (es) |
AU (3) | AU2011319843C1 (es) |
CA (2) | CA2815181C (es) |
ES (1) | ES2863626T3 (es) |
MX (2) | MX354481B (es) |
TW (2) | TWI636993B (es) |
WO (1) | WO2012058393A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2352532C (en) | 1998-11-27 | 2014-10-14 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
EP2552953B1 (en) | 2010-04-01 | 2017-05-17 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
EP3195880B1 (en) | 2010-05-14 | 2019-11-27 | Amgen Inc. | High concentration anti-sclerostin antibody formulations |
US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
TWI636993B (zh) * | 2010-10-27 | 2018-10-01 | 安美基公司 | Dkk1抗體及使用方法 |
CA2828000A1 (en) * | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
MY170720A (en) | 2011-03-25 | 2019-08-27 | Amgen Inc | Antibody formulations |
SI2739311T1 (en) | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
CA2858974A1 (en) | 2011-12-28 | 2013-07-04 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
EP2836512B1 (en) | 2012-04-11 | 2018-10-24 | F.Hoffmann-La Roche Ag | Improved antibody light chains |
JP6770312B2 (ja) | 2012-07-05 | 2020-10-14 | ユセベ ファルマ ソシエテ アノニム | 骨疾患の治療 |
EP2911691B1 (en) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014121196A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
US11135223B2 (en) | 2016-01-22 | 2021-10-05 | Yale University | Compositions and methods for inhibiting Dkk-1 |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ 3 リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
US11608374B2 (en) * | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
US20200317795A1 (en) * | 2017-10-04 | 2020-10-08 | Amgen Inc. | Transthyretin immunoglobulin fusions |
EP3768386A4 (en) * | 2018-03-23 | 2022-04-13 | University of Massachusetts | GENE THERAPEUTICS FOR THE TREATMENT OF BONE DISEASES |
WO2019191534A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
US20210079079A1 (en) * | 2018-05-02 | 2021-03-18 | Ortheus, Inc. | Systems and methods for local modulation of wnt signaling |
AU2020217012A1 (en) * | 2019-02-01 | 2021-08-19 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
TR201920272A1 (tr) * | 2019-12-15 | 2021-06-21 | Uludamar Altay | Dental i̇mplantlar, greft materyalleri̇ ve prf i̇le osseoi̇ntegrasyonun artirilmasi i̇çi̇n bi̇r terapöti̇k kompozi̇syon ve bunun lokal kullanim yöntemleri̇ |
WO2023143444A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
CA2111348A1 (en) | 1991-06-14 | 1992-12-23 | John S. Logan | Production of human hemoglobin in transgenic pigs |
JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
JP3589665B2 (ja) | 1992-10-23 | 2004-11-17 | イミュネックス・コーポレーション | 可溶性オリゴマー蛋白質の調製法 |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
KR100942002B1 (ko) | 1996-12-03 | 2010-02-12 | 암젠 프레몬트 인코포레이티드 | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체 |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6344541B1 (en) | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
EP1461442B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human ig lambda light chain genes |
EP2336177A1 (en) * | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
AR060017A1 (es) * | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
CN101641373B (zh) * | 2007-02-08 | 2015-02-11 | 默沙东公司 | Dkk-1的特异性抗体 |
TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
CN102388067A (zh) * | 2008-09-19 | 2012-03-21 | 米迪缪尼有限公司 | 定向于cd105的抗体及其用途 |
WO2010131185A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Inc. | Blocking anti-dkk-1 antibodies and their uses |
TWI636993B (zh) * | 2010-10-27 | 2018-10-01 | 安美基公司 | Dkk1抗體及使用方法 |
CA2828000A1 (en) * | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
SI2739311T1 (en) * | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
CA2858974A1 (en) * | 2011-12-28 | 2013-07-04 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2011
- 2011-10-27 TW TW100139221A patent/TWI636993B/zh active
- 2011-10-27 AR ARP110103984A patent/AR083740A1/es active IP Right Grant
- 2011-10-27 CA CA2815181A patent/CA2815181C/en active Active
- 2011-10-27 CA CA3085710A patent/CA3085710A1/en active Pending
- 2011-10-27 US US13/878,619 patent/US9879072B2/en active Active
- 2011-10-27 JP JP2013536812A patent/JP6066912B2/ja active Active
- 2011-10-27 WO PCT/US2011/058025 patent/WO2012058393A2/en active Application Filing
- 2011-10-27 AU AU2011319843A patent/AU2011319843C1/en active Active
- 2011-10-27 EP EP20213270.0A patent/EP3838922A1/en active Pending
- 2011-10-27 ES ES17169408T patent/ES2863626T3/es active Active
- 2011-10-27 TW TW105125647A patent/TWI636994B/zh active
- 2011-10-27 EP EP17169408.6A patent/EP3219725B1/en active Active
- 2011-10-27 MX MX2013004726A patent/MX354481B/es active IP Right Grant
- 2011-10-27 EP EP11779531.0A patent/EP2632951B1/en active Active
-
2013
- 2013-04-26 MX MX2021001494A patent/MX2021001494A/es unknown
-
2016
- 2016-06-03 AU AU2016203722A patent/AU2016203722A1/en not_active Abandoned
- 2016-09-08 JP JP2016175266A patent/JP6353500B2/ja active Active
-
2017
- 2017-12-13 US US15/841,065 patent/US10800839B2/en active Active
-
2018
- 2018-02-23 AU AU2018201333A patent/AU2018201333B2/en active Active
-
2020
- 2020-02-10 AR ARP200100356A patent/AR118047A2/es unknown
- 2020-09-09 US US17/015,212 patent/US20210040189A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001494A (es) | Anticuerpos dkk1 y metodos de uso. | |
MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
MX348637B (es) | Anticuerpos y composiciones anti-her3. | |
TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
EP2582722A4 (en) | ANTIBODIES AGAINST GD2 | |
NZ709059A (en) | Immunotherapy with binding agents | |
IN2014DN10386A (es) | ||
IN2012DN03883A (es) | ||
MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
GEP201706605B (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
IN2014KN02933A (es) | ||
EA201370018A1 (ru) | Составы рифаксимина и их применение | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
MX2011011768A (es) | Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos. | |
EA201171435A1 (ru) | Твердые фармацевтические композиции и способы их получения | |
MX357166B (es) | Anticuerpos que se unen a notum pectinacetilesterasa. | |
WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |